| Morgan T. Zurn | |
| Office: | Vice Chancellor of the Delaware Court of Chancery |
| Term Start: | October 4, 2018 |
| Appointer: | John Carney |
| Predecessor: | Seat established |
| Alma Mater: | University of Virginia (B.A.) University of Pennsylvania Law School (JD) |
Morgan T. Zurn is an American lawyer and judge on the Delaware Court of Chancery.
Zurn received a Bachelor of Arts degree from the University of Virginia and received her J.D. from the University of Pennsylvania Law School.[1] She began her career as a patent lawyer. She then served as a Deputy Attorney General at the Delaware Department of Justice.[2]
In September 2018, Governor John Carney nominated Zurn and Kathaleen McCormick to two new vice-chancellor positions on the Delaware Court of Chancery.[3] Carney praised Zurn's "breadth of knowledge, devotion to public service and passion for her work." She was confirmed by the Delaware Senate on October 3 and was sworn in on October 4.[4]
In September 2021, Zurn denied the defendants' motion to dismiss a stockholder derivative complaint based on the Boeing 737 MAX crashes that occurred in 2019.[5] [6] [7] Two months later, the defendants—members of Boeing's board of directors—settled the litigation for $237.5 million.[8] [9] The settlement agreement obligated Boeing to "add another director to its 12-member board with aviation, engineering or product-safety oversight experience" and to amend its bylaws to "memorialize the separation of the CEO and board chairmanship" roles that the company adopted in 2019 in response to the crashes.[10]
Also in September 2021, Zurn heard and decided DeMarco v. ChristianaCare Health Services, Inc.,[11] where the wife of a gravely ill COVID-19 patient sought an injunction forcing Wilmington Hospital to treat her husband with ivermectin.[12] [13] Zurn denied the requested injunction the morning after an expedited evidentiary hearing, holding "Patients, even gravely ill ones, do not have a right to a particular treatment, and medical providers' duty to treat is coterminous with their standard of care."[14] [15] [16] [17] Zurn's decision was cited favorably by courts addressing this issue around the country.[18]
In 2023, Zurn presided over the settlement approval process in stockholder litigation related to a "novel equity restructuring" proposed by AMC Theatres, a notable meme stock.[19] [20] On July 21, 2023, Zurn rejected the parties' proposed settlement that "would allow the company to issue more shares, sending common shares soaring" up "69% after the closing bell."[21] In her ruling, Zurn noted that an "unprecedented" number of stockholders—more than 2,800—objected to the proposed settlement. Zurn observed that "AMC's stockholder base is extraordinary" and that many AMC stockholders "care passionately about their stock ownership and the company."[21] On August 11, 2023, Zurn approved a revised settlement in the AMC case.[22]